Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis

NCT02921971 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis

Interventions

DRUG: SAR156597
DRUG: Placebo

Sponsor

Sanofi